⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VSTM News
Verastem, Inc.
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI ® FAKZYNJA ® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
businesswire.com
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
VSTM
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
businesswire.com
VSTM
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
businesswire.com
VSTM
Form 8-K
sec.gov
VSTM
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
businesswire.com
VSTM
Visiting Media Appoints Tom Cutsforth as Chief Financial Officer to Drive Global Scale
globenewswire.com
VSTM
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
businesswire.com
VSTM
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
businesswire.com
VSTM
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
businesswire.com
VSTM